Skip to main content

Table 2 Risk of bias judgments for included studies

From: Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages

Reference

Random sequence generation

Allocation concealment

Blinding of participants and personnel

Blinding of outcome assessment

Incomplete outcome data

Selective reporting

Other sources of bias

ADVANCE 2014

Low risk

Low risk

High risk

High risk

High risk

Low risk

High risk

AVANTAGE 2014

Unclear risk

Unclear risk

High risk

High risk

Unclear risk

Low risk

Low risk

BECOME 2009

Unclear risk

Unclear risk

High risk

High risk

Low risk

Low risk

High risk

BEYOND 2009

Low risk

Low risk

High risk

High risk

Unclear risk

Low risk

High risk

Bornstein 1987

Unclear risk

High risk

High risk

High risk

Low risk

Low risk

Low risk

BRAVO 2014

Low risk

Low risk

High risk

Low risk

Low risk

High risk

High risk

Calabrese 2012

Low risk

Low risk

High risk

High risk

Low risk

High risk

Low risk

CombiRx 2013

Low risk

Low risk

Low risk

Low risk

High risk

Low risk

Low risk

CONFIRM 2012

Low risk

Low risk

High risk

High risk

High risk

Low risk

High risk

Cop1 MSSG 1995

Unclear risk

Low risk

High risk

High risk

Low risk

Low risk

Low risk

ECGASG 2001

Low risk

Low risk

High risk

High risk

Low risk

Unclear risk

High risk

Etemadifar 2006

Unclear risk

Unclear risk

High risk

High risk

Low risk

Unclear risk

Unclear risk

EVIDENCE 2007

Low risk

Low risk

High risk

High risk

Low risk

Low risk

High risk

GALA 2013

Unclear risk

Low risk

High risk

High risk

Unclear risk

Low risk

High risk

GATE 2015

Low risk

Low risk

High risk

High risk

Low risk

Low risk

High risk

IFNB MSSG 1995

Unclear risk

Unclear risk

High risk

High risk

High risk

Low risk

High risk

IMPROVE 2012

Unclear risk

Low risk

Unclear risk

Unclear risk

Unclear risk

High risk

High risk

INCOMIN 2002

Low risk

Low risk

High risk

High risk

Low risk

Low risk

Low risk

Kappos 2011

Low risk

Low risk

High risk

High risk

Low risk

High risk

High risk

Knobler 1993

Unclear risk

Unclear risk

High risk

High risk

Unclear risk

Unclear risk

High risk

MSCRG 1996

Low risk

Unclear risk

Low risk

Low risk

High risk

Unclear risk

High risk

PRISMS 1998

Low risk

Low risk

Unclear risk

Low risk

Low risk

Low risk

High risk

REFORMS 2012

Low risk

Unclear risk

High risk

High risk

Unclear risk

Low risk

High risk

REGARD 2008

Low risk

Unclear risk

High risk

Low risk

Low risk

Low risk

High risk